216 related articles for article (PubMed ID: 24522170)
1. Comparison of efficacy and safety of once- versus twice-daily insulin detemir added on to oral antidiabetics in insulin-naive type 2 diabetes patients: 24-week, crossover, treat to target trial in a single center.
Cander S; Dizdar OS; Oz Gul O; Guclu M; Unal OK; Tuncel E; Erturk E; Imamoglu S; Ersoy C
Prim Care Diabetes; 2014 Oct; 8(3):256-64. PubMed ID: 24522170
[TBL] [Abstract][Full Text] [Related]
2. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
3. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
4. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.
Meneghini L; Kesavadev J; Demissie M; Nazeri A; Hollander P
Diabetes Obes Metab; 2013 Aug; 15(8):729-36. PubMed ID: 23421331
[TBL] [Abstract][Full Text] [Related]
5. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.
Meneghini LF; Dornhorst A; Sreenan S;
Curr Med Res Opin; 2009 Apr; 25(4):1029-35. PubMed ID: 19281426
[TBL] [Abstract][Full Text] [Related]
6. Metabolic control by insulin detemir in basal-bolus therapy: treat-to-target study in children and adolescents with type 1 diabetes.
Nimri R; Lebenthal Y; Shalitin S; Benzaquen H; Demol S; Phillip M
Pediatr Diabetes; 2013 May; 14(3):196-202. PubMed ID: 23289822
[TBL] [Abstract][Full Text] [Related]
7. Switching from twice-daily glargine or detemir to once-daily degludec improves glucose control in type 1 diabetes. An observational study.
Galasso S; Facchinetti A; Bonora BM; Mariano V; Boscari F; Cipponeri E; Maran A; Avogaro A; Fadini GP; Bruttomesso D
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1112-1119. PubMed ID: 27618501
[TBL] [Abstract][Full Text] [Related]
8. [Once daily insulin detemir in patients with type 2 diabetes: results of German centers in a 6-month international observational study (SOLVE)].
Liebl A; Wilhelm B; Kaiser M
MMW Fortschr Med; 2012 Dec; 154 Suppl 4():102-9. PubMed ID: 23326928
[TBL] [Abstract][Full Text] [Related]
9. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study.
King AB
Diabetes Obes Metab; 2009 Jan; 11(1):69-71. PubMed ID: 19120433
[TBL] [Abstract][Full Text] [Related]
10. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial.
Liebl A; Prager R; Binz K; Kaiser M; Bergenstal R; Gallwitz B;
Diabetes Obes Metab; 2009 Jan; 11(1):45-52. PubMed ID: 18643839
[TBL] [Abstract][Full Text] [Related]
11. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs.
Swinnen SG; Dain MP; Aronson R; Davies M; Gerstein HC; Pfeiffer AF; Snoek FJ; Devries JH; Hoekstra JB; Holleman F
Diabetes Care; 2010 Jun; 33(6):1176-8. PubMed ID: 20200301
[TBL] [Abstract][Full Text] [Related]
12. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
Rosenstock J; Davies M; Home PD; Larsen J; Koenen C; Schernthaner G
Diabetologia; 2008 Mar; 51(3):408-16. PubMed ID: 18204830
[TBL] [Abstract][Full Text] [Related]
13. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).
Yki-Järvinen H; Bergenstal R; Ziemen M; Wardecki M; Muehlen-Bartmer I; Boelle E; Riddle MC;
Diabetes Care; 2014 Dec; 37(12):3235-43. PubMed ID: 25193531
[TBL] [Abstract][Full Text] [Related]
14. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial.
Gough SC; Bhargava A; Jain R; Mersebach H; Rasmussen S; Bergenstal RM
Diabetes Care; 2013 Sep; 36(9):2536-42. PubMed ID: 23715753
[TBL] [Abstract][Full Text] [Related]
15. Comparison of once- versus twice-daily administration of insulin detemir, used with mealtime insulin aspart, in basal-bolus therapy for type 1 diabetes: assessment of detemir administration in a progressive treat-to-target trial (ADAPT).
Le Floch JP; Lévy M; Mosnier-Pudar H; Nobels F; Laroche S; Gonbert S; Eschwege E; Fontaine P;
Diabetes Care; 2009 Jan; 32(1):32-7. PubMed ID: 18945928
[TBL] [Abstract][Full Text] [Related]
16. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries.
Khunti K; Caputo S; Damci T; Dzida GJ; Ji Q; Kaiser M; Karnieli E; Liebl A; Ligthelm RJ; Nazeri A; Orozco-Beltran D; Pan C; Ross SA; Svendsen AL; Vora J; Yale JF; Meneghini LF;
Diabetes Obes Metab; 2012 Dec; 14(12):1129-36. PubMed ID: 22830956
[TBL] [Abstract][Full Text] [Related]
17. A crossover comparison of glycemic variations in Japanese patients with type 1 diabetes receiving insulin glargine versus insulin detemir twice daily using continuous glucose monitoring (CGM): J COLLECTION (Jikei COmparison of Lantus and LEvemir with Cgm for Thinking Insulin OptimizatioN).
Tsujino D; Nishimura R; Morimoto A; Tajima N; Utsunomiya K
Diabetes Technol Ther; 2012 Jul; 14(7):596-601. PubMed ID: 22775404
[TBL] [Abstract][Full Text] [Related]
18. A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes.
Fogelfeld L; Dharmalingam M; Robling K; Jones C; Swanson D; Jacober S
Diabet Med; 2010 Feb; 27(2):181-8. PubMed ID: 20546262
[TBL] [Abstract][Full Text] [Related]
19. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target.
Rosenstock J; Rodbard HW; Bain SC; D'Alessio D; Seufert J; Thomsen AB; Svendsen CB; DeVries JH;
J Diabetes Complications; 2013; 27(5):492-500. PubMed ID: 23746555
[TBL] [Abstract][Full Text] [Related]
20. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus.
Kabadi UM
Clin Drug Investig; 2008; 28(11):697-701. PubMed ID: 18840012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]